A Well-Structured Follow-Up Program is Required after Recovery from Coronavirus Disease 2019 (COVID-19); Release from Quarantine is Not the End of Treatment
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Subjects
2.2. Methods
2.2.1. A Follow-Up Health Consultation Program after Recovery from COVID-19
2.2.2. General Characteristics of the Subjects and their Symptoms before Release from Quarantine
2.2.3. Evaluation of Physical Condition after Release from Quarantine
2.2.4. Evaluation of Psychological Status after Release from Quarantine
2.2.5. Evaluation of Family Relationships after Release from Quarantine
2.2.6. Positive Test after COVID-19 Viral Clearance
2.3. Statistical Analysis
3. Results
3.1. The Participants in the Health Consultation Program
3.2. General Characteristics of the Subjects, and Symptoms Prior to Release from Quarantine
3.3. Physical and Psychological Status and Family Relationships after Release from Quarantine
3.4. Factors Affecting the Number of Consultations after Recovery from COVID-19
3.5. Positive Cases after Clearance of Virus and a Negative Test Result
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Korea Ministry of Health and Welfare and Centers for Disease Control and Prevention. Latest Updates. Available online: http://ncov.mohw.go.kr/en (accessed on 29 January 2021).
- Lai, C.C.; Shih, T.P.; Ko, W.C.; Tang, H.J.; Hsueh, P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents 2020, 55, 105924. [Google Scholar] [CrossRef] [PubMed]
- WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19—11 March 2020. Available online: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (accessed on 6 April 2020).
- Park, M.; Cook, A.R.; Lim, J.T.; Sun, Y.; Dickens, B.L. A Systematic Review of COVID-19 Epidemiology Based on Current Evidence. J. Clin. Med. 2020, 9, 967. [Google Scholar] [CrossRef] [Green Version]
- WHO. Q&A on Coronaviruses (COVID-19). Available online: https://www.who.int/news-room/q-a-detail/q-a-coronaviruses (accessed on 9 April 2020).
- Kwek, S.K.; Chew, W.M.; Ong, K.C.; Ng, A.W.; Lee, L.S.; Kaw, G.; Leow, M.K. Quality of life and psychological status in survivors of severe acute respiratory syndrome at 3 months postdischarge. J. Psychosom. Res. 2006, 60, 513–519. [Google Scholar] [CrossRef] [PubMed]
- Hong, X.; Currier, G.W.; Zhao, X.; Jiang, Y.; Zhou, W.; Wei, J. Posttraumatic stress disorder in convalescent severe acute respiratory syndrome patients: A 4-year follow-up study. Gen. Hosp. Psychiatry 2009, 31, 546–554. [Google Scholar] [CrossRef] [PubMed]
- Das, K.M.; Lee, E.Y.; Singh, R.; Enani, M.A.; Al Dossari, K.; Van Gorkom, K.; Larsson, S.G.; Langer, R.D. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J. Radiol. Imaging 2017, 27, 342–349. [Google Scholar] [CrossRef] [PubMed]
- Torales, J.; O’Higgins, M.; Castaldelli-Maia, J.M.; Ventriglio, A. The outbreak of COVID-19 coronavirus and its impact on global mental health. Int. J. Soc. Psychiatry 2020, 66, 317–320. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Carda, S.; Invernizzi, M.; Bavikatte, G.; Bensmaïl, D.; Bianchi, F.; Deltombe, T.; Draulans, N.; Esquenazi, A.; Francisco, G.E.; Gross, R.; et al. COVID-19 pandemic. What should Physical and Rehabilitation Medicine specialists do? A clinician’s perspective. Eur. J. Phys. Rehabil. Med. 2020, 56, 515–524. [Google Scholar] [CrossRef]
- Xing, Y.; Mo, P.; Xiao, Y.; Zhao, O.; Zhang, Y.; Wang, F. Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020. Eurosurveillance 2020, 25. [Google Scholar] [CrossRef]
- Ye, G.; Pan, Z.; Pan, Y.; Deng, Q.; Chen, L.; Li, J.; Li, Y.; Wang, X. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. J. Infect. 2020. [Google Scholar] [CrossRef]
- Kang, Y.J. South Korea’s COVID-19 Infection Status: From the Perspective of Re-positive Test Results After Viral Clearance Evidenced by Negative Test Results. Disaster Med. Public Health Prep. 2020, 1–3. [Google Scholar] [CrossRef]
- To, K.K.-W.; Hung, I.F.-N.; Ip, J.D.; Chu, A.W.-H.; Chan, W.-M.; Tam, A.R.; Fong, C.H.-Y.; Yuan, S.; Tsoi, H.-W.; Ng, A.C.-K.; et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin. Infect. Dis. 2020. [Google Scholar] [CrossRef]
- Kim, Y.A.; Lee, G.H.; Lee, K.M.; Ko, H.J.; Lee, D.; Kim, A.S. Communication and Cooperation Between the Medical Academy, Medical Association, and Local Government: Health Counseling Program After Recovery From Coronavirus Disease 2019 (COVID-19) in Daegu. Front. Public Health 2020, 8, 563757. [Google Scholar] [CrossRef]
- Rabinovitz, B.; Jaywant, A.; Fridman, C.B. Neuropsychological functioning in severe acute respiratory disorders caused by the coronavirus: Implications for the current COVID-19 pandemic. Clin. Neuropsychol. 2020, 34, 1453–1479. [Google Scholar] [CrossRef]
- Schnell, T.; Krampe, H. Meaning in Life and Self-Control Buffer Stress in Times of COVID-19: Moderating and Mediating Effects With Regard to Mental Distress. Front. Psychiatry 2020, 11, 582352. [Google Scholar] [CrossRef]
- Grover, S.; Sahoo, S.; Mehra, A.; Avasthi, A.; Tripathi, A.; Subramanyan, A.; Pattojoshi, A.; Rao, G.P.; Saha, G.; Mishra, K.K.; et al. Psychological impact of COVID-19 lockdown: An online survey from India. Indian J. Psychiatry 2020, 62, 354–362. [Google Scholar] [CrossRef]
- Kannan, S.; Shaik Syed Ali, P.; Sheeza, A.; Hemalatha, K. COVID-19 (Novel Coronavirus 2019)—Recent trends. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 2006–2011. [Google Scholar] [CrossRef]
- Sheleme, T.; Bekele, F.; Ayela, T. Clinical Presentation of Patients Infected with Coronavirus Disease 19: A Systematic Review. Infect. Dis. 2020, 13, 1178633720952076. [Google Scholar] [CrossRef]
- Jung, C.Y.; Park, H.; Kim, D.W.; Choi, Y.J.; Kim, S.W.; Chang, T.I. Clinical Characteristics of Asymptomatic Patients with COVID-19: A Nationwide Cohort Study in South Korea. Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis. 2020, 99, 266–268. [Google Scholar] [CrossRef]
- Jeong, T.H.; Pak, C.; Ock, M.; Lee, S.H.; Son, J.S.; Jeon, Y.J. Real Asymptomatic SARS-CoV-2 Infection Might Be Rare: Importance of Careful Interviews and Follow-up. J. Korean Med. Sci. 2020, 35. [Google Scholar] [CrossRef]
- Lavezzo, E.; Franchin, E.; Ciavarella, C.; Cuomo-Dannenburg, G.; Barzon, L.; Del Vecchio, C.; Rossi, L.; Manganelli, R.; Loregian, A.; Navarin, N.; et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’. Nature 2020, 584, 425–429. [Google Scholar] [CrossRef]
- Oran, D.P.; Topol, E.J. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. Ann. Intern. Med. 2020, 173, 362–367. [Google Scholar] [CrossRef] [PubMed]
- Kim, H.J.; Hwang, H.S.; Choi, Y.H.; Song, H.Y.; Park, J.S.; Yun, C.Y.; Ryu, S. The Delay in Confirming COVID-19 Cases Linked to a Religious Group in Korea. J. Prev. Med. Public Health 2020, 53, 164–167. [Google Scholar] [CrossRef] [PubMed]
- Jung, G.; Lee, H.; Kim, A.; Lee, U. Too Much Information: Assessing Privacy Risks of Contact Trace Data Disclosure on People With COVID-19 in South Korea. Front. Public Health 2020, 8, 305. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Clinical Management of COVID-19: Interim Guidance. Available online: https://apps.who.int/iris/handle/10665/332196 (accessed on 18 September 2020).
- Jang, J.G.; Hur, J.; Choi, E.Y.; Hong, K.S.; Lee, W.; Ahn, J.H. Prognostic Factors for Severe Coronavirus Disease 2019 in Daegu, Korea. J. Korean Med. Sci. 2020, 35, e209. [Google Scholar] [CrossRef]
- Herridge, M.S.; Moss, M.; Hough, C.L.; Hopkins, R.O.; Rice, T.W.; Bienvenu, O.J.; Azoulay, E. Recovery and outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family caregivers. Intensive Care Med. 2016, 42, 725–738. [Google Scholar] [CrossRef]
- Shepherd, S.; Batra, A.; Lerner, D.P. Review of Critical Illness Myopathy and Neuropathy. Neurohospitalist 2017, 7, 41–48. [Google Scholar] [CrossRef] [Green Version]
- Ohtake, P.J.; Lee, A.C.; Scott, J.C.; Hinman, R.S.; Ali, N.A.; Hinkson, C.R.; Needham, D.M.; Shutter, L.; Smith-Gabai, H.; Spires, M.C.; et al. Physical Impairments Associated With Post-Intensive Care Syndrome: Systematic Review Based on the World Health Organization’s International Classification of Functioning, Disability and Health Framework. Phys. Ther. 2018, 98, 631–645. [Google Scholar] [CrossRef] [Green Version]
- Cento, V.; Colagrossi, L.; Nava, A.; Lamberti, A.; Senatore, S.; Travi, G.; Rossotti, R.; Vecchi, M.; Casati, O.; Matarazzo, E.; et al. Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients. J. Infect. 2020, 81, e90–e92. [Google Scholar] [CrossRef]
- Yang, C.; Jiang, M.; Wang, X.; Tang, X.; Fang, S.; Li, H.; Zuo, L.; Jiang, Y.; Zhong, Y.; Chen, Q.; et al. Viral RNA level, serum antibody responses, and transmission risk in recovered COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: A population-based observational cohort study. Emerg. Microbes Infect. 2020, 9, 2368–2378. [Google Scholar] [CrossRef]
- Shi, F.; Wu, T.; Zhu, X.; Ge, Y.; Zeng, X.; Chi, Y.; Du, X.; Zhu, L.; Zhu, F.; Zhu, B.; et al. Association of viral load with serum biomakers among COVID-19 cases. Virology 2020, 546, 122–126. [Google Scholar] [CrossRef]
- Torres, D.A.; Ribeiro, L.; Riello, A.; Horovitz, D.D.G.; Pinto, L.F.R.; Croda, J. Reinfection of COVID-19 after 3 months with a distinct and more aggressive clinical presentation: Case report. J. Med. Virol. 2020. [Google Scholar] [CrossRef]
- AlFehaidi, A.; Ahmad, S.A.; Hamed, E. SARS-CoV-2 re-infection: A case report from Qatar. J. Infect. 2020. [Google Scholar] [CrossRef]
Total (n = 1604) | No. of Consultations | p * | ||
---|---|---|---|---|
Once (n = 1145) | Twice or More (n = 459) | |||
No. of consultations | 1.38 ± 0.79 | 1.00 | 2.34 ± 0.95 | <0.001 |
Age | 43.62 ± 16.32 | 43.46 ± 16.40 | 44.02 ± 16.13 | 0.765 |
Sex, male | 530 (33) | 381 (33.3) | 149 (32.5) | 0.754 |
Quarantine period (days) | 26.16 ± 9.99 | 26.32 ± 9.85 | 25.71 ± 10.33 | 0.376 |
ICU admission | 28 (1.7) | 15 (1.3) | 13 (2.8) | 0.035 |
Underlying disease | 366 (22.8) | 265 (23.1) | 101 (22.0) | 0.623 |
Hypertension | 206 (12.8) | 146 (12.8) | 60 (13.1) | 0.862 |
Diabetes | 95 (5.9) | 68 (5.9) | 27 (5.9) | 0.965 |
Dyslipidemia | 25 (1.6) | 20 (1.7) | 5 (1.1) | 0.337 |
Heart disease | 26 (1.6) | 16 (1.4) | 10 (2.2) | 0.263 |
Pulmonary disease | 27 (1.7) | 18 (1.6) | 9 (2.0) | 0.584 |
Allergic disease | 29 (1.8) | 22 (1.9) | 7 (1.5) | 0.590 |
Thyroid disease | 12 (0.7) | 8 (0.7) | 4 (0.9) | 0.751 † |
Kidney disease | 4 (0.2) | 3 (0.3) | 1 (0.2) | 1.000 † |
Any malignancies | 20 (1.2) | 17 (1.5) | 3 (0.7) | 0.175 |
Liver disease | 12 (0.7) | 7 (0.6) | 5 (1.1) | 0.341 † |
Neurologic disease | 17 (1.1) | 13 (1.1) | 4 (0.9) | 0.791 † |
Presence of symptoms before the diagnosis of COVID-19 | ||||
Asymptomatic | 408 (25.4) | 310 (27.1) | 98 (21.4) | 0.017 |
Any symptom | 1196 (74.6) | 835 (72.9) | 361 (78.6) | |
Fever | 342 (21.3) | 235 (20.5) | 107 (23.3) | 0.218 |
Cough, sputum | 346 (21.6) | 232 (20.3) | 114 (24.8) | 0.044 |
Sore throat, pharyngitis | 180 (11.2) | 126 (11.0) | 54 (11.8) | 0.663 |
Rhinorrhea, nasal congestion | 96 (6.0) | 71 (6.2) | 25 (5.4) | 0.565 |
Dysosmia, dysgeusia | 212 (13.2) | 150 (13.1) | 62 (13.5) | 0.828 |
Chest discomfort, dyspnea | 73 (4.6) | 40 (3.5) | 33 (7.2) | 0.001 |
Myalgia | 308 (19.2) | 223 (19.5) | 85 (18.5) | 0.660 |
Headache | 122 (7.6) | 86 (7.5) | 36 (7.8) | 0.821 |
Fatigue, malaise, lethargy | 28 (1.7) | 15 (1.3) | 13 (2.8) | 0.035 |
Diarrhea, abdominal discomfort | 61 (3.8) | 39 (3.4) | 22 (4.8) | 0.189 |
Total (n = 1604) | No. of Consultations | p * | ||
---|---|---|---|---|
Once (n = 1145) | Twice or More (n = 459) | |||
Physical symptoms after recovering from COVID-19 | ||||
Asymptomatic | 1171 (73.0) | 874 (76.3) | 297 (64.7) | <0.001 |
Any symptom | 433 (27.0) | 271 (23.7) | 162 (35.3) | <0.001 |
Fever | 10 (0.6) | 5 (0.4) | 5 (1.1) | |
Cough, sputum | 174 (10.9) | 116 (10.1) | 58 (12.6) | |
Sore throat, pharyngitis | 40 (2.5) | 23 (2.0) | 17 (3.7) | |
Rhinorrhea, nasal congestion | 33 (2.1) | 26 (2.3) | 7 (1.5) | |
Dysosmia, dysgeusia | 44 (2.7) | 27 (2.4) | 17 (3.7) | |
Chest discomfort, dyspnea | 38 (2.4) | 23 (2.0) | 15 (3.3) | |
Myalgia | 23 (1.4) | 13 (1.1) | 10 (2.2) | |
Headache | 23 (1.4) | 16 (1.4) | 7 (1.5) | |
Fatigue, malaise, lethargy | 40 (2.5) | 18 (1.6) | 22 (4.8) | |
Diarrhea, abdominal discomfort | 8 (0.5) | 4 (0.3) | 4 (0.9) | |
General physical status after recovering from COVID-19 | ||||
Much better than before | 31 (1.9) | 25 (2.2) | 6 (1.3) | 0.057 |
A little better than before | 138 (8.6) | 107 (9.3) | 31 (6.8) | |
Similar | 1085 (67.6) | 782 (68.3) | 303 (66.0) | |
A little worse than before | 314 (19.6) | 208 (18.2) | 106 (23.1) | |
Much worse than before | 36 (2.2) | 23 (2.0) | 13 (2.8) | |
Anxiety after recovering from COVID-19 | ||||
Not at all | 1075 (67.0) | 813 (71.0) | 262 (57.1) | <0.001 † |
Mild | 437 (27.2) | 284 (24.8) | 153 (33.3) | |
Moderate | 88 (5.5) | 47 (4.1) | 41 (8.9) | |
Severe | 4 (0.2) | 1 (0.1) | 3 (0.7) | |
Depressive mood after recovering from COVID-19 | ||||
Not at all | 1295 (80.7) | 970 (84.7) | 325 (70.8) | <0.001 † |
Mild | 244 (15.2) | 143 (12.5) | 101 (22.0) | |
Moderate | 61 (3.8) | 30 (2.6) | 31 (6.8) | |
Severe | 4 (0.2) | 2 (0.2) | 2 (0.4) | |
Insomnia after recovering from COVID-19 | ||||
Not at all | 1227 (76.5) | 920 (80.3) | 307 (66.9) | <0.001 |
Occasionally | 199 (12.4) | 125 (10.9) | 74 (16.1) | |
Frequently | 178 (11.1) | 100 (8.7) | 78 (17.0) | |
Psychological stress after recovering from COVID-19 | ||||
Not at all | 751 (46.8) | 585 (51.1) | 166 (36.2) | <0.001 |
Rarely | 417 (26.0) | 287 (25.1) | 130 (28.3) | |
Occasionally | 301 (18.8) | 203 (17.7) | 98 (21.4) | |
Frequently | 114 (7.1) | 60 (5.2) | 54 (11.8) | |
Very often | 21 (1.3) | 10 (0.9) | 11 (2.4) | |
Family relationships after recovering from COVID-19 | ||||
Closer than before | 97 (6.0) | 74 (6.5) | 23 (5.0) | 0.176 |
Unchanged | 1421 (88.6) | 1016 (88.7) | 405 (88.2) | |
Deteriorated | 86 (5.4) | 55 (4.8) | 31 (6.8) | |
Re-positive result of COVID-19 test | 35 (2.2) | 9 (0.8) | 26 (5.7) | <0.001 |
Factors | aOR | 95% CI | p * |
---|---|---|---|
Re-confirmed COVID-19 test | 6.703 | 3.062–14.674 | <0.001 |
Presence of physical symptoms after recovering from COVID-19 | |||
Asymptomatic | 1.000 | ||
Any symptom | 1.558 | 1.220–1.989 | <0.001 |
Depressive mood after recovering from COVID-19 | |||
Not at all | 1.000 | ||
Mild | 1.668 | 1.202–2.314 | 0.002 |
Moderate | 1.922 | 1.034–3.573 | 0.039 |
Severe | 1.961 | 0.268–14.374 | 0.508 |
Psychological stress after recovering from COVID-19 | |||
Not at all | 1.000 | ||
Rarely | 1.418 | 1.072–1.874 | 0.014 |
Occasionally | 1.182 | 0.843–1.658 | 0.331 |
Frequently | 2.029 | 1.248–3.299 | 0.004 |
Very often | 1.963 | 0.751–5.130 | 0.169 |
Characteristics of Re-Confirmed Cases (n = 35) | |
---|---|
Age, years | 49.11 ± 15.35 |
Sex, male | 8 (22.9) |
Quarantine period (days) | 31.49 ± 10.86 |
ICU admission | 2 (5.7) |
Underlying disease | 8 (22.9) |
Hypertension | 7 (20.0) |
Dyslipidemia | 1 (2.9) * |
Neurologic disease | 1 (2.9) † |
Purpose of COVID-19 re-test | |
For their remaining symptoms | 12 (34.3) |
For returning to work or health care facilities | 23 (65.7) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lee, K.-M.; Ko, H.-J.; Lee, G.H.; Kim, A.-S.; Lee, D.-W. A Well-Structured Follow-Up Program is Required after Recovery from Coronavirus Disease 2019 (COVID-19); Release from Quarantine is Not the End of Treatment. J. Clin. Med. 2021, 10, 2329. https://doi.org/10.3390/jcm10112329
Lee K-M, Ko H-J, Lee GH, Kim A-S, Lee D-W. A Well-Structured Follow-Up Program is Required after Recovery from Coronavirus Disease 2019 (COVID-19); Release from Quarantine is Not the End of Treatment. Journal of Clinical Medicine. 2021; 10(11):2329. https://doi.org/10.3390/jcm10112329
Chicago/Turabian StyleLee, Keun-Mi, Hae-Jin Ko, Geon Ho Lee, A-Sol Kim, and Dong-Wook Lee. 2021. "A Well-Structured Follow-Up Program is Required after Recovery from Coronavirus Disease 2019 (COVID-19); Release from Quarantine is Not the End of Treatment" Journal of Clinical Medicine 10, no. 11: 2329. https://doi.org/10.3390/jcm10112329
APA StyleLee, K. -M., Ko, H. -J., Lee, G. H., Kim, A. -S., & Lee, D. -W. (2021). A Well-Structured Follow-Up Program is Required after Recovery from Coronavirus Disease 2019 (COVID-19); Release from Quarantine is Not the End of Treatment. Journal of Clinical Medicine, 10(11), 2329. https://doi.org/10.3390/jcm10112329